These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473 [TBL] [Abstract][Full Text] [Related]
4. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Bose B; Badve SV; Hiremath SS; Boudville N; Brown FG; Cass A; de Zoysa JR; Fassett RG; Faull R; Harris DC; Hawley CM; Kanellis J; Palmer SC; Perkovic V; Pascoe EM; Rangan GK; Walker RJ; Walters G; Johnson DW Nephrol Dial Transplant; 2014 Feb; 29(2):406-13. PubMed ID: 24042021 [TBL] [Abstract][Full Text] [Related]
5. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Liu X; Zhai T; Ma R; Luo C; Wang H; Liu L Ren Fail; 2018 Nov; 40(1):289-297. PubMed ID: 29619870 [TBL] [Abstract][Full Text] [Related]
6. Time to target uric acid to retard CKD progression. Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448 [TBL] [Abstract][Full Text] [Related]
7. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease. Ghane Sharbaf F; Assadi F Pediatr Nephrol; 2018 Aug; 33(8):1405-1409. PubMed ID: 29549464 [TBL] [Abstract][Full Text] [Related]
8. Effects of Allopurinol on the Progression of Chronic Kidney Disease. Badve SV; Pascoe EM; Tiku A; Boudville N; Brown FG; Cass A; Clarke P; Dalbeth N; Day RO; de Zoysa JR; Douglas B; Faull R; Harris DC; Hawley CM; Jones GRD; Kanellis J; Palmer SC; Perkovic V; Rangan GK; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW; N Engl J Med; 2020 Jun; 382(26):2504-2513. PubMed ID: 32579811 [TBL] [Abstract][Full Text] [Related]
9. Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis. Zhang YF; He F; Ding HH; Dai W; Zhang Q; Luan H; Lv YM; Zeng HB J Huazhong Univ Sci Technolog Med Sci; 2014 Aug; 34(4):476-481. PubMed ID: 25135714 [TBL] [Abstract][Full Text] [Related]
10. Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients. Li Y; Liu M; Zhang X; Lu Y; Meng J Ren Fail; 2019 Nov; 41(1):595-599. PubMed ID: 31267805 [TBL] [Abstract][Full Text] [Related]
11. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Lee JW; Lee KH Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease . Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634 [TBL] [Abstract][Full Text] [Related]
13. Safety of urate-lowering therapies: managing the risks to gain the benefits. Keenan RT Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576 [TBL] [Abstract][Full Text] [Related]
14. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study. Rodenbach KE; Schneider MF; Furth SL; Moxey-Mims MM; Mitsnefes MM; Weaver DJ; Warady BA; Schwartz GJ Am J Kidney Dis; 2015 Dec; 66(6):984-92. PubMed ID: 26209544 [TBL] [Abstract][Full Text] [Related]
15. Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study. Liu C; Zhao Q; Zhen Y; Gao Y; Tian L; Wang L; Ji L; Liu G; Ji Z; Liu K Can J Cardiol; 2013 Sep; 29(9):1048-54. PubMed ID: 23395281 [TBL] [Abstract][Full Text] [Related]